Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
3.485 USD | +3.72% | +22.28% | +54.96% |
Mar. 20 | North American Morning Briefing : Markets on Hold -2- | DJ |
Mar. 19 | JPMorgan Upgrades Mersana Therapeutics to Neutral From Underweight, Price Target is $5 | MT |
Business Summary
Number of employees: 123
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Antibody Drug Conjugate
100.0
%
| 27 | 100.0 % | 37 | 100.0 % | +38.65% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 27 | 100.0 % | 37 | 100.0 % | +38.65% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Martin Huber
CEO | Chief Executive Officer | 64 | 20-04-12 |
Director of Finance/CFO | 46 | 19-07-09 | |
David Mott
CHM | Chairman | 58 | 12-07-30 |
Timothy Lowinger
CTO | Chief Tech/Sci/R&D Officer | 60 | 08-01-31 |
Anna Protopapas
BRD | Director/Board Member | 59 | 15-03-01 |
Mohan Bala
PRN | Corporate Officer/Principal | - | 21-10-24 |
Chuck Miller
LAW | General Counsel | - | 20-08-30 |
Ashish Mandelia
AUD | Comptroller/Controller/Auditor | 50 | 19-06-30 |
Tushar Misra
PRN | Corporate Officer/Principal | 64 | 21-08-15 |
General Counsel | 50 | 21-04-25 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Kristen Hege
BRD | Director/Board Member | 60 | 16-07-31 |
David Mott
CHM | Chairman | 58 | 12-07-30 |
Anna Protopapas
BRD | Director/Board Member | 59 | 15-03-01 |
Andrew Hack
BRD | Director/Board Member | 50 | 17-01-05 |
Martin Huber
CEO | Chief Executive Officer | 64 | 20-04-12 |
Lawrence Alleva
BRD | Director/Board Member | 74 | 17-09-04 |
Allene Diaz
BRD | Director/Board Member | 59 | 21-03-08 |
Willard Dere
BRD | Director/Board Member | 70 | 18-03-18 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 122,361,236 | 120,325,959 ( 98.34 %) | 0 | 98.34 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+44.83% | 411M | |
-1.65% | 103B | |
+6.75% | 101B | |
+5.71% | 23.07B | |
-12.60% | 22.23B | |
-9.70% | 18.05B | |
-39.98% | 17.18B | |
-10.17% | 16.94B | |
+6.12% | 14.07B | |
+35.47% | 12.35B |
- Stock Market
- Equities
- MRSN Stock
- Company Mersana Therapeutics, Inc.